![](/images/graphics-bg.png)
Myelodysplastic Syndrome and Histone Deacetylase Inhibitors : “To Be or Not to Be Acetylated”?
Joint Authors
Alinger, Beate
Kemmerling, Ralf
Stintzing, Sebastian
Neureiter, Daniel
Ocker, Matthias
Kiesslich, Tobias
Source
Journal of Biomedicine and Biotechnology
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-15, 15 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-05-15
Country of Publication
Egypt
No. of Pages
15
Main Subjects
Abstract EN
Myelodysplastic syndrome (MDS) represents a heterogeneous group of diseases with clonal proliferation, bone marrow failure and increasing risk of transformation into an acute myeloid leukaemia.
Structured guidelines are developed for selective therapy based on prognostic subgroups, age, and performance status.
Although many driving forces of disease phenotype and biology are described, the complete and possibly interacting pathogenetic pathways still remain unclear.
Epigenetic investigations of cancer and haematologic diseases like MDS give new insights into the pathogenesis of this complex disease.
Modifications of DNA or histones via methylation or acetylation lead to gene silencing and altered physiology relevant for MDS.
First clinical trials give evidence that patients with MDS could benefit from epigenetic treatment with, for example, DNA methyl transferase inhibitors (DNMTi) or histone deacetylase inhibitors (HDACi).
Nevertheless, many issues of HDACi remain incompletely understood and pose clinical and translational challenges.
In this paper, major aspects of MDS, MDS-associated epigenetics and the potential use of HDACi are discussed.
American Psychological Association (APA)
Stintzing, Sebastian& Kemmerling, Ralf& Kiesslich, Tobias& Alinger, Beate& Ocker, Matthias& Neureiter, Daniel. 2011. Myelodysplastic Syndrome and Histone Deacetylase Inhibitors : “To Be or Not to Be Acetylated”?. Journal of Biomedicine and Biotechnology،Vol. 2011, no. 2011, pp.1-15.
https://search.emarefa.net/detail/BIM-455088
Modern Language Association (MLA)
Stintzing, Sebastian…[et al.]. Myelodysplastic Syndrome and Histone Deacetylase Inhibitors : “To Be or Not to Be Acetylated”?. Journal of Biomedicine and Biotechnology No. 2011 (2011), pp.1-15.
https://search.emarefa.net/detail/BIM-455088
American Medical Association (AMA)
Stintzing, Sebastian& Kemmerling, Ralf& Kiesslich, Tobias& Alinger, Beate& Ocker, Matthias& Neureiter, Daniel. Myelodysplastic Syndrome and Histone Deacetylase Inhibitors : “To Be or Not to Be Acetylated”?. Journal of Biomedicine and Biotechnology. 2011. Vol. 2011, no. 2011, pp.1-15.
https://search.emarefa.net/detail/BIM-455088
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-455088